Pawan Kumar

Dr. Pawan Kumar


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 November 2023 in Vaccines
Verified
Journal Article
Open access
PDF file
PKPawan Kumar
Pawan Kumar
ACAshish Birendra Chakraborty
Ashish Birendra Chakraborty
SDSuhas Dhandore
Suhas Dhandore
PDPritu Dhalaria
Pritu Dhalaria
ASAjeet Kumar Singh
Ajeet Kumar Singh
GTGunjan Taneja
Gunjan Taneja
The COVID-19 pandemic posed substantial challenges to healthcare systems globally and severely disrupted essential health services, including routine immunization programs. In India, these disruptions were exacerbated due to the sudden emergence of the pandemic and lockdown measures, leading to mass migrations and a shortage of healthcare workers. Caregivers’ concerns about routine immunization sessions further compounded the problem, resulting in a sharp increase in zero-dose children. This review paper examines India’s strategies for conducting one of the world’s largest COVID-19 vaccination programs while effectively restoring and perpetuating its Universal Immunization Program (UIP). The UIP played a pivotal role in sustaining immunization services during the pandemic, ultimately improving immunization coverage compared to pre-pandemic levels. India’s accomplishments in this regard are highlighted through key performance indicators, the reach of immunization services, a reduction in zero-dose children, and antigen-wise coverage. The paper also discusses the successful integration of COVID-19 vaccination within the UIP framework, underscoring the significance of existing infrastructure, technology, and capacity building. India’s dedication to concurrently managing routine immunization and COVID-19 vaccination showcases the adaptability and resilience of its healthcare system. India’s journey serves as a global example of efficient mass immunization during challenging times, emphasizing the importance of political will, healthcare infrastructure investment, skilled healthcare workforces, and comprehensive vaccination programs. In a world grappling with the dual challenge of COVID-19 and routine immunization, India’s experience provides a roadmap for strengthening healthcare systems and promoting public health as the critical agenda in challenging times.

21 April 2025 in Vaccines
Verified
Journal Article
Open access
PDF file
PKPawan Kumar
Pawan Kumar
ARArindam Ray
Arindam Ray
ASAmrita Singh
Amrita Singh
ASAbida Sultana
Abida Sultana
RHRhythm Hora
Rhythm Hora
ADArup DebRoy
Arup DebRoy
Background: Globally, pneumonia claims the lives of about 700,000 children under the age of 5 every year. Pneumococcal conjugate vaccine (PCV) was introduced in India phase-wise, beginning in high-burden states, and the rollout was completed nationwide by 2021—representing a major initiative by the Ministry of Health and Family Welfare (MoHFW). Despite the challenges posed by the COVID-19 pandemic, the campaign succeeded in maintaining progress and achieving nationwide coverage. This narrative review highlights the significant decisions, processes, and coordinated efforts of the various stakeholders involved that led to this successful PCV rollout. Methodology: A comprehensive desk review of both published and unpublished literature relevant to pneumonia burden and the efficacy and effectiveness of PCVs, along with documentation of PCV introduction and the scale-up was carried out. Results: The documentation of the PCV journey has been broken down into four sections: pre-introduction, PCV Phase-I introduction, pan-India rapid expansion, and the period post-introduction. Since the nationwide rollout in 2021, PCV coverage in India has steadily increased, reflecting successful immunization efforts. WUENIC, which is an annual WHO, and UNICEF estimates of national immunization coverage also show a positive trend in vaccination coverage (PCV booster coverage = 25% (2021), rising to 83% (2023), aligning with the goals of the WHO and UNICEF’s Global Action Plan for the Prevention and Control of Pneumonia and Diarrhoea (GAPPD). Conclusions: The phased rollout was an ambitious effort by the MoHFW, which was particularly challenging given the overlap with the COVID-19 pandemic. Despite these hurdles, the MoHFW, along with strong collaboration from development partners and stakeholders, successfully navigated the complex rollout. Future studies on the role of PCVs in reducing antibiotic resistance and the economic benefits of PCV introduction could help policymakers sustain funding and prioritize vaccine procurement decisions.

20 March 2025 in Vaccines
Verified
Journal Article
Open access
PDF file
PKPawan Kumar
Pawan Kumar
RMRashmi Mehra
Rashmi Mehra
ARArindam Ray
Arindam Ray
ASAmrita Singh
Amrita Singh
KSKapil Singh
Kapil Singh
ADArup DebRoy
Arup DebRoy
Introduction: In 2023, India’s National Technical Advisory Group on Immunization (NTAGI) recommended the inclusion of typhoid conjugate vaccine (TCV) in the Universal Immunization Programme (UIP). However, introducing TCV, an additional injectable vaccine (AIV), will potentially increase the number of injections administered in a single visit to a maximum of five (if given at the 9 to 12 months touchpoint) or four (if given in the second year of life). In this context, the present study aimed to explore the perspectives of program managers, service providers, and caregivers regarding introduction of an AIV in a single visit under the UIP. Methods: A mixed-method study was undertaken wherein quantitative data was collected by telephonic surveys, and qualitative data by key informant interviews (KIIs) and focus group discussions (FGDs). Purposive sampling encompassed eight states, eight districts, eight planning units, and 32 session sites. The qualitative data were thematically analyzed manually using Excel, while the quantitative data was analyzed using STATA 17. Results: A total of 1140 telephonic surveys, 96 KIIs, and 16 FGDs were conducted. The study revealed that program managers mentioned maternal emotional reactions as a significant concern and backed AIV introduction at the 9–12 months touchpoint. Vaccinators and community mobilizers favored the 16–24 months window with combined presentations and mentioned single-dose vials as the preferred approach for vaccine delivery. Caregivers acknowledged the benefits of vaccination but expressed discomfort and fear regarding multiple injections to the child in a single visit. Caregivers expressed a preference for a combination vaccine. No preference was reported among caregivers for the introduction of AIV to the 9–12 or 16–24 months touchpoints. Conclusion: Stakeholders’ perspectives on introducing an additional injectable vaccine in a single visit under the UIP are diverse. These will be helpful in developing an effective strategy for the future introduction of AIV under UIP.

20 February 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
PKPawan Kumar
Pawan Kumar
ARArindam Ray
Arindam Ray
ASAmrita Singh
Amrita Singh
ASAbida Sultana
Abida Sultana
RHRhythm Hora
Rhythm Hora
ADArup DebRoy
Arup DebRoy
Background: Pneumonia is one of the leading causes of death in under-5 children in India. The phased rollout, which began in high-burden states and was completed nationwide by 2021, was a major initiative by the Ministry of Health and Family Welfare (MoHFW). Despite challenges posed by the COVID-19 pandemic, which affected logistics and required creative solutions, the campaign succeeded in maintaining progress and achieving nationwide coverage. This narrative review highlights the significant decisions, dedication and coordinated efforts of various stakeholders involved that led to accomplishment of successful PCV rollout. Methodology: A comprehensive desk review of both published and unpublished literature relevant to the burden of pneumonia, pneumococcal pneumonia mortality in children under five, the efficacy and effectiveness of Pneumococcal Conjugate Vaccines (PCVs), and the documentation of PCV introduction and scale-up in India was carried out. Results: The documentation of PCV journey has been broken down in four sections: pre-introduction, PCV Phase I introduction, Pan India rapid expansion, and post-introduction. Since the nationwide rollout in 2021, PCV coverage in India has steadily increased reflecting successful immunization efforts. The WHO/UNICEF Estimates of National Immunization Coverage (WUENIC) also show a positive trend in vaccination coverage, which aligns with the goals of the WHO and UNICEF’s Global Action Plan for the Prevention and Control of Pneumonia and Diarrhoea (GAPPD). Conclusion: The phased rollout, starting with high-burden states and completing nationwide expansion by 2021, was an ambitious effort by the Ministry of Health and Family Welfare (MoHFW), particularly challenging given the overlap with the COVID-19 pandemic. Despite these hurdles, the MoHFW, with strong collaboration from development partners and stakeholders, successfully navigated the complex rollout. This is a noteworthy achievement considering the unprecedented scale of the COVID-19 vaccination drive that was simultaneously ongoing.

27 August 2026 in Vaccines
Verified
Journal Article
Open access
PDF file
PKPawan Kumar
Pawan Kumar
PDPritu Dhalaria
Pritu Dhalaria
SKSanjay Kapur
Sanjay Kapur
Ajay VermaAjay Verma
Ajay Verma
ASAjeet Kumar Singh
Ajeet Kumar Singh
ARArindam Ray
Arindam Ray
Introduction: India’s immunization initiatives are among the largest globally, characterized by a substantial birth cohort of 27 million children annually, and have achieved significant progress in increasing coverage through the UIP. However, there are still challenges that persist, and multiple determinants contribute to the existing challenges; migration is one of them. Migration has always been a key driver of socio-economic and demographic changes, particularly in low and middle-income countries (LMICs). Specifically, there is a need to better understand the vulnerabilities of immunization among recent migrants. To examine this, the study explores the association between a mother’s recent migration and the full immunization coverage of children aged 12–23 months in India. Data & Methods: Our study utilized data from the National Family Health Survey-5 (2019–21). The outcome variable of interest in this study is the full immunization among children aged 12–23 months (receipt of all basic vaccinations). The primary predictor variable in this study was recent maternal migration, defined as the mother’s duration of residence at the current place of residence. We used a series of multivariate logistic regression models to examine the relationship between full Immunization among children and maternal migration status, with some data restrictions in the models. Results: The results show a 17 percentage-point difference in full immunization between children of migrant and non-migrant mothers. The adjusted odds ratios of children of mothers who had recently migrated had significantly lower odds of full immunization (aOR: 0.39, 95% CI: 0.35–0.43) compared to children whose mothers had not recently migrated. Even across the household wealth quintile and social groups, the recent migration of the mother was associated with being less likely to be fully immunized among children 12–23 months. Conclusions: The findings of this study provide significant quantitative evidence that recent migration (less than 3 years) of mother is a key factor influencing Immunization coverage and is a predictor of full immunization among children aged 12–23 months in India. The recent migration was consistently linked with lower odds of full immunization coverage across different household wealth levels and social groups. This study suggests that children of recently migrated mother are a vulnerable subgroup of the population at risk of not receiving full immunization among children aged 12–23 months.